No Data
No Data
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study
Express News | Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing
Express News | Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy